Which strategy to choose when planning a drug discovery project? May be structure-based design, ligand-based design or de novo design? These questions are discussed in this second post in our series on structure-based drug design.
Do we really need structural biology services companies for drug discovery? In this first post on structural biology and drug discovery we discuss the basic idea behind the need for structural biology services.
A new consortium aimed at leveraging the partners ́ technology platforms for accelerating structure-based drug discovery targeting a “weak spot” in the Sars-CoV-2 virus replication machinery, the NSP10 protein.